•  Net sales amounted to TSEK 2,368 (1,939).
•  The loss after tax amounted to TSEK 8,906 (9 656).
•  The loss per share amounted to SEK 0.54 (0.58).
•  The cash flow from current operations was negative in the amount of TSEK 8,950 (9 682).
•  The gross margin increased to 52.6% (46.4%).
•  Electrode sales in volume increased by 47% and reached 6,080 (4,134) units. Repeat sales of electrodes to existing customers increased by 59%.

•  Sales on the company's key market Germany increased by 23% in the quarter following record electrode sales. 
•  The first supplement to the US PMA approval for Nevisense was approved, and Nevisense 2 was launched in the US.

• A new study was published that opened up the skin barrier assessment application for SciBase's product Nevisense. The paper, entitled `Direct assessment of skin epithelial barrier by electrical impedance spectroscopy', was published online in the journal Allergy, European Journal of Allergy and Clinical Immunology.
• Nevisense was included in US and European investigator-initiated studies utilizing Nevisense for skin barrier function assessment.
• The notice of the AGM 2019 was published April 8th.
• The annual report 2018 was published on April 25th. 

Apr 1 2018 -
Jan 1 - Mar 31 Mar 31 2019 Jan 1 - Dec 31
THE GROUP 2019 2018 Rolling-12 2018
Net sales, SEK ths 2 368 1 939 7 327 6 899
Gross margin, % 52,6% 46,4% 53,7% 52,0%
Equity/Asset ratio, % 79,0% 91,9% 86,6% 88,1%
Net indebtness, multiple 0,27 0,09 0,15 0,13
Cash equivalents, SEK ths 58 057 95 542 58 057 67 514
Cashflow from operating -8 950 -9 682 -36 751 -37 482
activities, SEK ths
Earnings per share -0,54 -0,58 -2,62 -2,66
(before and after
dilution), SEK
Shareholder's equity per 3,78 6,38 7,98 4,30
share, SEK
Average number of shares, 16 618 16 618 10 576 16 618
000'
Number of shares at 16 618 16 618 16 618 16 618
closing of period, 000'
Share price at end of 4,14 7,45 4,14 3,10
period, SEK
Number of sold 6 080 4 134 14 512 12 566
electrodes, pieces
Average number of 19 20 20 19
employees

This interim report has not been subject to review by the Company's auditors.This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 10, 2019.

Contact person: Michael Colérus, CFO. +46 70 341 34 72

For more information, please contact: 
Simon Grant, CEO SciBase 
Phone: +46 72 887 43 99 
Email: simon.grant@scibase.com

Certified Advisor: 
Avanza AB 
Phone: +46 8 409 421 20 
Email: corp@avanza.se

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and a US FDA-approval (PMA). Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on Nasdaq First North ("SCIB"). Further information is available at www.scibase.com.